Determined and creative, Vanda adopted a strategy for expedited approval as a first-in-class drug to treat Non-24, an orphan disease. Instead of testing tasimelteon rigorously in the general population, the testing could involve dozens rather than tens of thousands of patients, and could last six months instead of years. It could more readily focus on highly fungible surrogate endpoints.
